92 pending office actions • 15 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19323227 | Untitled | VIELA BIO, INC. | GODDARD, LAURA B | 1642 | Non-Final OA | |
| 19313405 | CAPSULE FORMULATIONS | Chemocentryx, Inc. | SONG, JIANFENG | 1613 | Final Rejection | Aug 28, 2025 |
| 19312046 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen, Inc. | KOSTURKO, GEORGE W | 1621 | Non-Final OA | Aug 27, 2025 |
| 19309299 | SOTORASIB DOSING REGIMEN | Amgen, Inc. | KOSTURKO, GEORGE W | 1621 | Final Rejection | Aug 25, 2025 |
| 19281019 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen, Inc. | SIMMONS, CHRIS E | 1622 | Non-Final OA | Jul 25, 2025 |
| 18934755 | SUSTAINABLE AND MODULAR PACKAGING SYSTEMS FOR CONTAINERS FOR PHARMACEUTICAL USE | Amgen, Inc. | ORTIZ, RAFAEL ALFREDO | 3736 | Non-Final OA | Nov 01, 2024 |
| 18857085 | SYSTEMS AND METHODS FOR CONFIGURING A ROBOT TO INTERFACE WITH EQUIPMENT | Amgen, Inc. | BUI, NHI QUYNH | 3656 | Non-Final OA | Oct 15, 2024 |
| 18835139 | Visual Inspection Systems for Containers of Liquid Pharmaceutical Products | Amgen, Inc. | PEREZ-GUZMAN, CARLOS GABRIEL | 2877 | Non-Final OA | Aug 01, 2024 |
| 18696948 | Heterocyclic Compounds and Methods of Use | Amgen, Inc. | NOLAN, JASON MICHAEL | 1623 | Non-Final OA | Mar 28, 2024 |
| 18602268 | ANION EXCHANGE CHROMATOGRAPHY PROCESSES USING A PRIMARY AMINE LIGAND | Amgen, Inc. | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | Non-Final OA | Mar 12, 2024 |
| 18684262 | METHODS COMPRISING THERAPEUTIC COMPOUNDS AND IN VITRO MAMMALIAN SKIN | Amgen, Inc. | CLARKE, TRENT R | 1651 | Non-Final OA | Feb 16, 2024 |
| 18435746 | TIGIT AND CD112R BLOCKADE | Amgen, Inc. | GAO, ASHLEY HARTMAN | 1678 | Non-Final OA | Feb 07, 2024 |
| 18681252 | ISOLATION OF THERAPEUTIC PROTEIN | Amgen, Inc. | HOLLAND, PAUL J | 1656 | Non-Final OA | Feb 05, 2024 |
| 18411245 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | Chemocentryx, Inc. | MCMILLIAN, KARA RENITA | 1623 | Final Rejection | Jan 12, 2024 |
| 18535068 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | Amgen, Inc. | LANDSMAN, ROBERT S | 1647 | Non-Final OA | Dec 11, 2023 |
| 18562107 | SOTORASIB DOSING REGIMEN | Amgen, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | Non-Final OA | Nov 17, 2023 |
| 18503009 | DOSING REGIMEN OF KRAS G12C INHIBITOR | Amgen, Inc. | AULAKH, CHARANJIT | 1621 | Non-Final OA | Nov 06, 2023 |
| 18502780 | NOVEL PRMT5 INHIBITORS | Amgen, Inc. | COLEMAN, BRENDA LIBBY | 1624 | Non-Final OA | Nov 06, 2023 |
| 18558827 | SOTORASIB FORMULATION | Amgen, Inc. | GOTFREDSON, GAREN | 1619 | Non-Final OA | Nov 03, 2023 |
| 18288410 | ETELCALCETIDE FORMULATIONS | Amgen, Inc. | LEE, JIA-HAI | 1658 | Non-Final OA | Oct 26, 2023 |
| 18556998 | METHODS FOR REDUCING LOW MOLECULAR WEIGHT SPECIES OF RECOMBINANTLY-PRODUCED PROTEINS | Amgen Research (Munich) GmbH | SZPERKA, MICHAEL EDWARD | 1641 | Non-Final OA | Oct 24, 2023 |
| 18381745 | DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF | Amgen, Inc. | LI, RUIXIANG | 1674 | Non-Final OA | Oct 19, 2023 |
| 18376677 | REDUCING IMMUNOGENICITY TO PEGLOTICASE | Horizon Therapeutics Usa, Inc. | BORI, IBRAHIM D | 1629 | Non-Final OA | Oct 04, 2023 |
| 18285125 | MAGEB2 BINDING CONSTRUCTS | Amgen, Inc. | JOHANSEN, PETER N. | 1644 | Non-Final OA | Sep 29, 2023 |
| 18284590 | MODULATING PRODUCT QUALITY OF ASYMMETRIC MULTISPECIFIC ANTIBODIES THROUGH THE USE OF TEMPERATURE | Amgen, Inc. | AEDER, SEAN E | 1642 | Non-Final OA | Sep 28, 2023 |
| 18550647 | DRUG DELIVERY DEVICE | Amgen, Inc. | FREHE, WILLIAM R | 3783 | Non-Final OA | Sep 14, 2023 |
| 18241564 | LEAN PERFUSION CELL CULTURE METHODS | Amgen, Inc. | BARRON, SEAN C | 1653 | Non-Final OA | Sep 01, 2023 |
| 18548484 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland Dac | DONOGHUE, BRITTNEY ERIN | 1675 | Non-Final OA | Aug 30, 2023 |
| 18264216 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | Amgen, Inc. | O DELL, DAVID K | 1621 | Non-Final OA | Aug 03, 2023 |
| 18224463 | FORMULATED RECEPTOR POLYPEPTIDES AND RELATED METHODS | Amgen, Inc. | MCCOLLUM, ANDREA K | 1674 | Non-Final OA | Jul 20, 2023 |
| 18270581 | USE OF KRAS G12C INHIBITOR IN TREATING CANCERS | Amgen, Inc. | HASTINGS, ALISON AZAR | 1627 | Non-Final OA | Jun 30, 2023 |
| 18255575 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | Amgen, Inc. | PECKHAM, RICHARD GRANT | 1627 | Non-Final OA | Jun 01, 2023 |
| 18324056 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland Dac | LUNDE, GRACE HENRY | 1641 | Non-Final OA | May 25, 2023 |
| 18038579 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | Amgen, Inc. | MOORE, SUSANNA | 1624 | Non-Final OA | May 24, 2023 |
| 18037128 | REAL TIME PCR METHOD TO DETECT BOVINE PARVOVIRUS 3 | Amgen, Inc. | SIFFORD, JEFFREY MARK | 1671 | Non-Final OA | May 16, 2023 |
| 18316739 | Antibody Constructs for CLDN18.2 and CD3 | Amgen, Inc. | MOSELEY II, NELSON B | 1642 | Non-Final OA | May 12, 2023 |
| 18251553 | MATERIALS AND METHODS FOR PROTEIN PROCESSING | Amgen, Inc. | BANERJEE, KOYELI | 1658 | Non-Final OA | May 03, 2023 |
| 18035054 | METHODS FOR ADMINISTERING A BCMAXCD3 BINDING MOLECULE | Amgen, Inc. | HADDAD, MAHER M | 1641 | Non-Final OA | May 02, 2023 |
| 18034620 | OVEREXPRESSION OF INSULIN-LIKE GROWTH FACTOR RECEPTOR MUTANTS TO MODULATE IGF SUPPLEMENTATION | Amgen, Inc. | RAHMAN, MASUDUR | 1633 | Non-Final OA | Apr 28, 2023 |
| 18305165 | ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME | VIELA BIO, INC. | MERTZ, PREMA MARIA | 1674 | Non-Final OA | Apr 21, 2023 |
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | VIELA BIO, INC. | DAHLE, CHUN WU | 1641 | Non-Final OA | Apr 19, 2023 |
| 18031691 | RELATIVE UNPAIRED GLYCANS IN ANTIBODY PRODUCTION METHODS | Amgen, Inc. | ROBINSON, HOPE A | 1652 | Non-Final OA | Apr 13, 2023 |
| 18248979 | ANTI-C-C CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE THEREOF | Five Prime Therapeutics, Inc. | FAUST, AMBER KATHLEEN | 1643 | Non-Final OA | Apr 13, 2023 |
| 18248345 | RATIONAL SELECTION OF BUILDING BLOCKS FOR THE ASSEMBLY OF MULTISPECIFIC ANTIBODIES | Amgen, Inc. | HUYNH, PHUONG N | 1641 | Non-Final OA | Apr 07, 2023 |
| 18030685 | PROCESS FOR RACEMIZING AND ISOLATING ATROPISOMERS OF 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | Amgen, Inc. | RAHMANI, NILOOFAR | 1691 | Non-Final OA | Apr 06, 2023 |
| 18296211 | AMORPHOUS AND CRYSTALLINE FORMS OF MCL-1 ANTAGONISTS | Amgen, Inc. | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | Non-Final OA | Apr 05, 2023 |
| 18029995 | POLYVINYL SULFONATE DETECTION AND REMOVAL FROM BIOMOLECULE COMPOSITIONS | Amgen, Inc. | HORLICK, KENNETH R | 1681 | Non-Final OA | Apr 03, 2023 |
| 18189712 | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease | Celimmune LLC | WEN, SHARON X | 1641 | Non-Final OA | Mar 24, 2023 |
| 18245004 | METHODS OF DETECTING ISOASPARTIC ACID | Amgen, Inc. | XU, XIAOYUN | 1797 | Final Rejection | Mar 13, 2023 |
| 18044158 | MATERIALS AND METHODS TO REDUCE PROTEIN AGGREGATION | Amgen, Inc. | ALLEN, MARIANNE P | 1647 | Final Rejection | Mar 06, 2023 |
| 18042267 | ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION | Amgen, Inc. | BRISTOL, LYNN ANNE | 1643 | Non-Final OA | Feb 20, 2023 |
| 18020761 | METHODS OF TREATING GOUT | Horizon Therapeutics Usa, Inc. | LEESER, ERICH A | 1622 | Non-Final OA | Feb 10, 2023 |
| 18018389 | CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME | Amgen, Inc. | VAN BUREN, LAUREN K | 1638 | Non-Final OA | Jan 27, 2023 |
| 18007560 | RNAI CONSTRUCTS FOR INHIBITING HSD17B13 EXPRESSION AND METHODS OF USE THEREOF | Amgen, Inc. | SHIN, DANA H | 1635 | Non-Final OA | Dec 01, 2022 |
| 17928561 | ANTIBODY FORMULATIONS AND USES THEREOF | Amgen, Inc. | KIM, YUNSOO | 1641 | Non-Final OA | Nov 29, 2022 |
| 18057637 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | Horizon Therapeutics Ireland Dac | FORD, VANESSA L | 1674 | Non-Final OA | Nov 21, 2022 |
| 17923347 | Deep Learning Platforms for Automated Visual Inspection | Amgen, Inc. | HICKS, AUSTIN JAMES | 2124 | Non-Final OA | Nov 04, 2022 |
| 17774125 | METHODS FOR TREATING LEUKEMIA | Amgen, Inc. | BENAVIDES, JENNIFER ANN | 1675 | Non-Final OA | Oct 31, 2022 |
| 17916843 | Synthesis of vinylic alcohol intermediates | Amgen, Inc. | HAVLIN, ROBERT H | 1626 | Non-Final OA | Oct 04, 2022 |
| 17913629 | MONOCLONAL ANTIBODIES TO CHEMICALLY-MODIFIED NUCLEIC ACIDS AND USES THEREOF | Amgen, Inc. | EMCH, GREGORY S | 1678 | Non-Final OA | Sep 22, 2022 |
| 17818256 | FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT | Five Prime Therapeutics, Inc. | DUFFY, BRADLEY | 1643 | Final Rejection | Aug 08, 2022 |
| 17810142 | STABLE CYCLODEXTRIN FREE CARFILZOMIB FORMULATION | Amgen, Inc. | BASQUILL, SEAN M | 1614 | Non-Final OA | Jun 30, 2022 |
| 17786375 | INTERLEUKIN-2 IN COMBINATION WITH TNF RECEPTOR FAMILY MEMBERS FOR THE EXPANSION OF T-REGULATORY CELLS | Amgen, Inc. | PATTERSON, SARAH COOPER | 1675 | Final Rejection | Jun 16, 2022 |
| 17751586 | CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF | Kite Pharma, Inc. | NATARAJAN, MEERA | 1643 | Final Rejection | May 23, 2022 |
| 17778361 | NOVEL MULTISPECIFIC ANTIBODY FORMAT | Amgen, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | Non-Final OA | May 19, 2022 |
| 17776622 | HEMATOPOIETIC PRECURSOR CELL PRODUCTION | Amgen, Inc. | PRONZATI, GINA | 1633 | Final Rejection | May 13, 2022 |
| 17775543 | DOSAGE REGIMEN FOR ANTI-EGFRVIII AGENTS | Amgen Research (Munich) GmbH | CHASE, CAROL ANN | 1646 | Final Rejection | May 09, 2022 |
| 17775257 | METHOD OF TREATING OR AMELIORATING CUSHING'S SYNDROME USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | Amgen, Inc. | ALLEN, MARIANNE P | 1647 | Non-Final OA | May 06, 2022 |
| 17775063 | ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES | Amgen, Inc. | DUFFY, BRADLEY | 1643 | Final Rejection | May 06, 2022 |
| 17773886 | HIGH SALT LOAD CONDITIONING DURING CATION EXCHANGE CHROMATOGRAPHY TO REMOVE PRODUCT-RELATED IMPURITIES | Amgen, Inc. | DEBERRY, REGINA M | 1647 | Non-Final OA | May 03, 2022 |
| 17773892 | HIGH SALT WASHES DURING CATION EXCHANGE CHROMATOGRAPHY TO REMOVE PRODUCT-RELATED IMPURITIES | Amgen, Inc. | SHELTON, SYNPHANE LA'SHAWN | 1652 | Non-Final OA | May 03, 2022 |
| 17773800 | CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN REGIMENS | Five Prime Therapeutics, Inc. | DENT, ALANA HARRIS | 1643 | Non-Final OA | May 02, 2022 |
| 17763824 | METHODS OF PRODUCING ANTIBODY COMPOSITIONS | Amgen, Inc. | IVICH, FERNANDO NMN | 1678 | Final Rejection | Mar 25, 2022 |
| 17686766 | MAMMALIAN CELL CULTURE | Amgen, Inc. | REGLAS, GEORGIANA C | 1651 | Non-Final OA | Mar 04, 2022 |
| 17640177 | IL-22 ORAL, INTRA-RECTAL, OR OTHER GUT-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | Amgen, Inc. | GURLEY, JAMI MICHELLE | 1647 | Non-Final OA | Mar 03, 2022 |
| 17632330 | KIF18A INHIBITORS | Amgen, Inc. | MAHLUM, JONATHAN DAVIS | 1625 | Final Rejection | Feb 02, 2022 |
| 17624824 | MULTISPECIFIC TRANSTHYRETIN IMMUNOGLOBULIN FUSIONS | Amgen, Inc. | LEE, JIA-HAI | 1658 | Non-Final OA | Jan 04, 2022 |
| 17620645 | PURIFICATION METHODS FOR CARBOHYDRATE-LINKED OLIGONUCLEOTIDES | Amgen, Inc. | GALSTER, SAMUEL LEONARD | 1693 | Final Rejection | Dec 17, 2021 |
| 17616366 | METHODS OF IDENTIFYING ATTRIBUTES OF THERAPEUTIC PROTEINS | Amgen, Inc. | SIMMONS, VALERIE MICHELLE | 1758 | Final Rejection | Dec 03, 2021 |
| 17616616 | SYSTEMS FOR PERFORMING CELLULAR ANALYSIS AND RELATED DEVICES FOR CONDITIONING ENVIRONMENTS ADJACENT CHIPS IN SUCH SYSTEMS | Amgen, Inc. | TURK, NEIL N | 1798 | Non-Final OA | Dec 03, 2021 |
| 17615520 | RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF | Amgen, Inc. | SULLIVAN, STEPHANIE LAUREN | 1635 | Non-Final OA | Nov 30, 2021 |
| 17609363 | MODULATING ANTIBODY EFFECTOR FUNCTIONS | Amgen, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | Final Rejection | Nov 05, 2021 |
| 17436696 | GROWTH DIFFERENTIATION FACTOR 15 COMBINATION THERAPY | Amgen, Inc. | SZPERKA, MICHAEL EDWARD | 1641 | Final Rejection | Sep 07, 2021 |
| 17436218 | IN VIVO REVERSIBILITY OF HIGH MOLECULAR WEIGHT SPECIES | Amgen, Inc. | FRITCHMAN, REBECCA M | 1758 | Non-Final OA | Sep 03, 2021 |
| 17401114 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | Amgen, Inc. | VYAS, KEYUR ANILKUMAR | 1637 | Final Rejection | Aug 12, 2021 |
| 17277533 | PLATFORM ASSEMBLY PROCESS FOR DRUG DELIVERY DEVICE | Amgen, Inc. | LALONDE, ALEXANDRA ELIZABETH | 3783 | Final Rejection | Mar 18, 2021 |
| 17264386 | DOSING REGIMEN FOR BCMA-CD3 BISPECIFIC ANTIBODIES | Amgen, Inc. | PETRASH, HILARY ANN | 1644 | Final Rejection | Jan 29, 2021 |
| 17262962 | PHARMACEUTICAL FORMULATIONS OF MASKED ANTIBODIES | Amgen, Inc. | SWARTWOUT, BRIANNA KENDALL | 1644 | Non-Final OA | Jan 25, 2021 |
| 17036690 | DRUG DELIVERY DEVICE | Amgen, Inc. | LALONDE, ALEXANDRA ELIZABETH | 3783 | Final Rejection | Sep 29, 2020 |
| 16763515 | METHODS FOR PRODUCING PROTEIN PRODUCTS | Amgen, Inc. | HURST, JONATHAN M | 1799 | Final Rejection | May 12, 2020 |
| 16869793 | DOSING REGIMEN FOR ANTI-BCMA AGENTS | Amgen, Inc. | BRISTOL, LYNN ANNE | 1643 | Non-Final OA | May 08, 2020 |
| 16799441 | ANTI-ILT7 ANTIBODY | Sbi Biotech Co., Ltd. | JUEDES, AMY E | 1644 | Final Rejection | Feb 24, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial